drugset
drugset / Trial / NCT06157918

Relative Bioavailability and Food Effect of SYHA1813 Oral Solution in Healthy Participants

NCT06157918 ↗

Phase 1 Completed 19 enrolled Shanghai Runshi Pharmaceutical Technology Co., Ltd
RandomizedCrossoverOpen-labelTreatment

Summary

This is a three-period crossover phase I study designed to evaluate the relative bioavailability, food effect, safety and tolerability of SYHA1813 oral solution in healthy participants.

Timeline

Start
2023-12-20
Primary completion
2024-01-26
Completion
2024-01-26

Drugs

EvaluationDrugModalityDoseRoute
Subject SYHA1813 Unknown 25 mg Oral
Subject SYHA1813 Unknown 200 mg Oral

Indications

No indication recorded.